Imbria Pharmaceuticals
Boston, US · Founded 2018 · Delaware corporation · 7 known investors
Founders & leadership
PC
Pavan CheruvuExecutive
AS
Alvin ShihExecutive
KJ
Komal JoshiExecutive
PB
Pieter BoelhouwerNamed on SEC filing
DC
David-Alexandre C. GrosNamed on SEC filing
Board
CD
Charles DunnBoard director
LR
Luse RebeccaBoard director
AL
Andrew LevinBoard director
ZA
Zina Affas BesseBoard director
KH
Ken HorneBoard director
Investors · 7
Catalio Capital ManagementreportedNew York
RA CapitalreportedBoston
SV Health InvestorsreportedBoston · $1M – $20M
Also in the syndicate · 4
AN VenturesAXA IM AltsCytokinetics, Inc.Deep Track Capitallead
Reported raises · per SEC filings
Form D private placements$147.7M disclosed across 3 rounds · 2018–2025
▶$66.7MraisedDec 2025 · 10 investors · BiotechnologyRule 506(b)
▶$66.7MraisedDec 2025 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Pavan CheruvuDirector
- Charles DunnDirector
- Alvin ShihExecutive Officer, Director
- Luse RebeccaDirector
- Ken HorneDirector
- Komal JoshiExecutive Officer
- Andrew LevinDirector
- Zina Affas BesseDirector
- Offering amount
- $144.2M
- Amount sold
- $66.7M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.7MraisedJul 2020 · 4 investors · PharmaceuticalsRule 506(b)
▶$40.7MraisedJul 2020 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew LevinDirector
- David-Alexandre C. GrosExecutive Officer
- James JanuzziDirector
- Offering amount
- $80.7M
- Amount sold
- $40.7M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$40.2MraisedJul 2018 · 3 investors · PharmaceuticalsRule 506(b)
▶$40.2MraisedJul 2018 · 3 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Andrew LevinDirector
- Pieter BoelhouwerDirector
- David-Alexandre C. GrosExecutive Officer, Director
- Offering amount
- $40.2M
- Amount sold
- $40.2M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Imbria Pharmaceuticals's investors?
- Imbria Pharmaceuticals's investors include Catalio Capital Management, RA Capital, SV Health Investors.
- How much funding has Imbria Pharmaceuticals raised?
- Imbria Pharmaceuticals has disclosed $147.7M raised across 3 rounds.
- Where is Imbria Pharmaceuticals headquartered?
- Imbria Pharmaceuticals is headquartered in Boston, US.